Labcorp's Alzheimer's Blood Test Launch Sparks 43.36% Trading Volume Surge Shares Rise 1.95% as Stock Ranks 426th in Market Activity

On August 19, 2025, Labcorp (LH) reported a trading volume of $230 million, a 43.36% increase from the prior day, ranking 426th in market activity. Shares rose 1.95% to $270.49, reflecting renewed investor interest in the diagnostic services provider.

The company launched the Lumipulse pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood test for Alzheimer’s disease. This in-vitro diagnostic tool enables non-invasive detection of amyloid plaques with 92% positive predictive value and 97% negative predictive value, replacing an earlier version introduced in April 2025. The test aligns with recent Alzheimer’s Association guidelines advocating blood-based biomarkers for specialized care settings, enhancing Labcorp’s role in early neurodegenerative disease diagnosis.

Industry dynamics support long-term growth, as the global Alzheimer’s diagnostics market is projected to expand at an 11% annual rate through 2030. Labcorp’s nationwide network of 2,200+ service centers ensures broad accessibility, while its recent AI-driven Test Finder tool further strengthens operational efficiency. The test targets adults aged 50+ with cognitive decline symptoms, though it is not marketed as a standalone screening solution.

Historical data shows Labcorp’s shares outperformed the medical industry, gaining 19.8% over the past year. While the company maintains a Zacks Rank #3 (Hold), broader market adoption of non-invasive diagnostics could drive valuation re-rating. However, execution risks include regulatory scrutiny and reimbursement challenges for novel biomarker-based tests.

A backtest of a strategy buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to 2025 yielded a 31.52% total return over 365 days, with an average 0.98% daily return. This highlights short-term momentum potential but underscores volatility inherent in volume-driven strategies.